<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1081</article-id><article-id pub-id-type="doi">10.24287/j.1081</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The impact of local inflammation on hemostasis and pathological thrombosis</article-title><trans-title-group xml:lang="ru"><trans-title>Оценка влияния локального воспаления на гемостаз и патологический тромбоз</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-4799-5565</contrib-id><name-alternatives><name xml:lang="en"><surname>Nikitin</surname><given-names>N. S.</given-names></name><name xml:lang="ru"><surname>Никитин</surname><given-names>Н. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Allergist-Immunologist at the Immunology Department</p></bio><bio xml:lang="ru"><p>врач-аллерголог-иммунолог отделения иммунологии</p></bio><email>nikita.nikitin@dgoi.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5623-723X</contrib-id><name-alternatives><name xml:lang="en"><surname>Bykov</surname><given-names>G. A.</given-names></name><name xml:lang="ru"><surname>Быков</surname><given-names>Г. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>nikita.nikitin@dgoi.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2930-8768</contrib-id><name-alternatives><name xml:lang="en"><surname>Obydennyi</surname><given-names>S. I.</given-names></name><name xml:lang="ru"><surname>Обыденный</surname><given-names>С. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>nikita.nikitin@dgoi.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8128-7757</contrib-id><name-alternatives><name xml:lang="en"><surname>Panteleev</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Пантелеев</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>nikita.nikitin@dgoi.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Center for Theoretical Problems of Physical and Chemical Pharmacology, Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">ФГБУН Центр теоретических проблем физико-химической фармакологии Российской академии наук</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">The M.V. Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-04-14" publication-format="electronic"><day>14</day><month>04</month><year>2026</year></pub-date><volume>25</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>91</fpage><lpage>98</lpage><history><date date-type="received" iso-8601-date="2026-02-02"><day>02</day><month>02</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-02-06"><day>06</day><month>02</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/1081">https://hemoncim.com/jour/article/view/1081</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Local inflammation commonly accompanies wounds, yet its impact on the dynamics of thrombus formation and hemostatic clot architecture remains poorly explored.</p> <p><bold>Aim:</bold> to investigate the influence of local inflammation on the dynamics of clot formation and hemostatic clot architecture.</p> <p><bold>Material and methods.</bold> In our models, we used 6–12-week-old ICR mice. Local inflammation was induced by a subcutaneous or intraperitoneal injection of hydroxyethyl cellulose gel containing lipopolysaccharide (LPS) (50 µg). Pathological thrombosis was assessed in a FeCl<sub>3</sub>-induced carotid artery thrombosis model with fluorescence imaging. Hemostatic clots were assessed in a kidney bleeding model followed by histological staining for fibrin/fibrinogen, CD41, and nuclei.</p> <p><bold>Results.</bold> In the FeCl<sub>3</sub>-induced arterial model, there were no significant differences between the control group and the local inflammation group (LPS group) in the time to initial thrombus formation (406 ± 189 s vs 522 ± 338 s; <italic>p</italic> &gt; 0.05), the maximal thrombus height (560 ± 65 µm vs 650 ± 73 µm; <italic>p</italic> &gt; 0.05), and the initial rate of clot growth (1 × 10<sup>–4</sup> ± 8 × 10<sup>–5</sup> mm<sup>2</sup>/s vs 4 × 10<sup>–4 </sup>± 6 × 10<sup>–5</sup> mm<sup>2</sup>/s; <italic>p</italic> &gt; 0.05). However, the residual thrombus height was higher in the LPS group (250 ± 237 µm vs 595 ± 107 µm; <italic>p </italic>&lt; 0.05). In the kidney bleeding model, the area of CD41 signal (3900 ± 1800 µm<sup>2</sup> vs 47 000 ± 44 000 µm<sup>2</sup>; <italic>p</italic> &gt; 0.05) and the area of signal from fibrinogen (117 000 ± 33 000 µm<sup>2</sup> vs 120 000 ± 120 000 µm<sup>2</sup>; <italic>p</italic> &gt; 0.05) did not differ between the control group and the LPS group, whereas the nuclear signal area was reduced in the LPS group (11 000 ± 9000 µm<sup>2</sup> vs 3200 ± 400 µm<sup>2</sup>; <italic>p</italic> &lt; 0.05).</p> <p><bold>Conclusion. </bold>Local LPS-driven inflammation does not accelerate early FeCl<sub>3</sub>-induced thrombus formation but is associated with increased thrombus persistence. In large tissue wounds, it does not measurably alter the fibrin-platelet component of the hemostatic clot while reducing nucleated cell accumulation.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Локальное воспаление часто сопровождает ранения, однако его влияние на динамику тромбообразования и архитектуру гемостатического сгустка изучено недостаточно.</p> <p><bold>Цель исследования</bold> – изучение влияния локального воспаления на динамику тромбообразования и архитектуру гемостатического сгустка.</p> <p><bold>Материалы и методы.</bold> В моделях использованы мыши ICR (6–12 недель), локальное воспаление воспроизводилось подкожной/внутрибрюшинной инъекцией геля гидроксиэтилцеллюлозы с липополисахаридом 50 мкг. Патологический тромбоз оценивали в модели FeCl<sub>3</sub>-индуцированного тромбоза сонной артерии с флуоресцентной визуализацией. Гемостатические сгустки оценивали в модели почечного кровотечения с последующей гистологической окраской на фибрин/фибриноген, CD41 и ядра.</p> <p><bold>Результаты.</bold> В артериальной модели время начала тромбообразования не отличалось между контролем и моделью локального воспаления (406 ± 189 с против 522 ± 338 с; <italic>p</italic> &gt; 0,05), как и максимальная высота тромба (560 ± 65 мкм против 650 ± 73 мкм; <italic>p</italic> &gt; 0,05) и его начальная скорость роста (1 × 10<sup>–4</sup> ± 8 × 10<sup>–5</sup> мм<sup>2</sup>/с против 4 × 10<sup>–4</sup> ± 6 × 10<sup>–5</sup> мм<sup>2</sup>/с;<italic> p </italic>&gt; 0,05). При этом остаточная высота тромба была выше в модели локального воспаления (250 ± 237 мкм против 595 ± 107 мкм; <italic>p</italic> &lt; 0,05). В модели почечного кровотечения площади тромбоцитарного сигнала (3900 ± 1800 мкм<sup>2 </sup>против 47 000 ± 44 000 мкм<sup>2</sup>; <italic>p</italic> &gt; 0,05) и сигнала от фибриногена (117 000 ± 33 000 мкм<sup>2</sup> против 120 000 ± 120 000 мкм<sup>2</sup>; <italic>p</italic> &gt; 0,05) не различались, тогда как площадь ядерного сигнала снижалась при липополисахариде (11 000 ± 9000 мкм<sup>2</sup> против 3200 ± 400 мкм<sup>2</sup>; <italic>p</italic> &lt; 0,05).</p> <p><bold>Заключение.</bold> Локальное воспаление, вызванное введением липополисахарида, не ускоряет раннее FeCl<sub>3</sub>-индуцированное тромбообразование, однако ассоциируется с более длительной персистенцией тромба. При крупных ранениях локальное воспаление значимо не изменяет фибриновый/тромбоцитарный компонент гемостатического сгустка, но в то же время снижает накопление ядросодержащих клеток.</p></trans-abstract><kwd-group xml:lang="en"><kwd>local inflammation</kwd><kwd>hemostasis</kwd><kwd>thrombosis</kwd><kwd>lipopolysaccharide</kwd><kwd>FeCl3</kwd><kwd>fibrin</kwd><kwd>platelets</kwd><kwd>immune cells</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>локальное воспаление</kwd><kwd>гемостаз</kwd><kwd>тромбоз</kwd><kwd>липополисахарид</kwd><kwd>FeCl3</kwd><kwd>фибрин</kwd><kwd>тромбоциты</kwd><kwd>иммунные клетки</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Российский научный фонд</institution></institution-wrap><institution-wrap><institution xml:lang="en">Russian Science Foundation</institution></institution-wrap></funding-source><award-id>23-75-10120</award-id></award-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Российский научный фонд</institution></institution-wrap><institution-wrap><institution xml:lang="en">Russian Science Foundation</institution></institution-wrap></funding-source><award-id>23-44-00082</award-id></award-group><funding-statement xml:lang="en">The experiments were conducted with the support of a grant from the Russian Science Foundation: on the renal bleeding model – project No. 23-75-10120; on the FeCl3-induced thrombosis model – project No. 23-44-00082</funding-statement><funding-statement xml:lang="ru">Эксперименты выполнены при финансовой поддержке гранта Российского научного фонда: с моделью почечного кровотечения – №23-75-10120, с моделью FeCl3-индуцированного тромбоза сонной артерии – №23-44-00082</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Hoffman M. The tissue factor pathway and wound healing. Semin Thromb Hemost 2018;44(2):142–50. DOI: 10.1055/s-0037-1604090</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Gaertner F., Massberg S. Migrating platelets are mechano-scavengers that collect and bundle bacteria. Cell 2017;171(6):1368–82.e23. DOI: 10.1016/j.cell.2017.11.001</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Brinkmann V., Reichard U., Goosmann C., Reichard U., Goosmann C., Fauler B. et al. Neutrophil extracellular traps kill bacteria. Science 2004;303(5663):1532–5. DOI: 10.1126/science.1092385</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Shi Y., Gauer J.S., Baker S.R., Philippou H., Connell S.D., Ariëns R.A.S. Neutrophils can promote clotting via FXI and impact clot structure via neutrophil extracellular traps in a distinctive manner in vitro. Sci Rep 2021;11(1):1718. DOI: 10.1038/s41598-021-81268-7</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Свешникова А.Н., Адаманская Е.А., Коробкина Ю.-Д.Д., Пантелеев М.А. Внутриклеточная сигнализация при феномене запрограммированной гибели нейтрофилов с появлением внеклеточных ДНК-ловушек при тромбообразовании. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2024;23(2):222–30. DOI:10.24287/1726-1708-2024-23-2-222-230 [Sveshnikova A.N., Adamanskaya E.A., Korobkina Yu.-D.D., Panteleev M.A. Intracellular signaling involved in the programmed neutrophil cell death leading to the release of extracellular DNA traps in thrombus formation. Pediatric Hematology/Oncology and Immunopathology 2024;23(2):222–30. (In Russ.)].</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest 2012;122(7):2331–6. DOI: 10.1172/JCI60229</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Von Brühl M.L., Stark K., Steinhart A., Chandraratne S., Konrad I., Lorenz M. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012;209(4):819–35. DOI: 10.1084/jem.20112322</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Schmidt C.Q., Verschoor A. Complement and coagulation: so close, yet so far. Blood 2017;130(24):2581–2. DOI: 10.1182/blood-2017-10-842575</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Yang X., Cheng X., Tang Y., Qiu X., Wang Y., Kang H. et al. Bacterial endotoxin activates the coagulation cascade through gasdermin D-dependent phosphatidylserine exposure. Immunity 2019;51(6):983–96.e6. DOI: 10.1016/j.immuni.2019.11.005</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Burzynski L.C., Humphry M., Pyrillou K., Wiggins K.A., Chan J.N.E., Figg N. et al. The coagulation and immune systems are directly linked through the activation of interleukin-1a by thrombin. Immunity 2019;50(4):1033–42.e6. DOI: 10.1016/j.immuni.2019.03.003</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Beristain-Covarrubias N., Perez-Toledo M., Thomas M.R., Henderson I.R., Watson S.P., Cunningham A.F. Understanding infection-induced thrombosis: lessons learned from animal models. Front Immunol 2019;10:2569. DOI: 10.3389/fimmu.2019.02569</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Schumski A., Ortega-Gómez A., Wichapong K., Winter C., Lemnitzer P., Viola J.R. et al. Endotoxinemia accelerates atherosclerosis via electrostatic charge-mediated monocyte adhesion. Circulation 2021;143(3):254–66. DOI: 10.1161/CIRCULATIONAHA.120.046677</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wang X. Lipopolysaccharide augments venous and arterial thrombosis in the mouse. Thromb Res 2008;123(2):355–60. DOI: 10.1016/j.thromres.2008.03.015</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Valladolid C., Martinez-Vargas M., Sekhar N., Lam F., Brown C., Palzkill T. et al. Modulating the rate of fibrin formation and clot structure attenuates microvascular thrombosis in systemic inflammation. Blood Adv 2020;4(7):1340–9. DOI: 10.1182/bloodadvances.2020001500</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Sadowski M., Ząbczyk M., Undas A. Low-grade lipopolysaccharide-related endotoxemia alters coronary thrombus composition and fibrin clot properties in patients with acute ST-segment elevation myocardial infarction. Kardiol Pol 2024;82(11):1127–30. DOI: 10.33963/v.phj.102310</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Schmidtchen A., Puthia M. Real-time in vivo imaging of LPS-induced local inflammation and drug deposition in NF-kB reporter mice. Bio Protoc 2020;10(16):e3724. DOI: 10.21769/BioProtoc.3724</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Rittie L. Cellular mechanisms of skin repair in humans and other mammals. J Cell Commun Signal. 2016;10(2):103–20. DOI: 10.1007/s12079-016-0330-1</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Macrae F.L., Duval C., Papareddy P., Baker S.R., Yuldasheva N., Kearney K.J. et al. A fibrin biofilm covers blood clots and protects from microbial invasion. J Clin Invest 2018;128(8):3356–68. DOI: 10.1172/JCI98734</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Yakusheva A.A., Butov K.R., Bykov G.A., Závodszky G., Eckly A., Ataullakhanov F.I. et al. Traumatic vessel injuries initiating hemostasis generate high shear conditions. Blood Adv 2022;6(16):4834–46. DOI: 10.1182/bloodadvances.2022006996</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Shen F., Kastrup C.J., Liu Y., Ismagilov R.F. Threshold response of initiation of blood coagulation by tissue factor in patterned microfluidic capillaries is controlled by shear rate. Arterioscler Thromb Vasc Biol 2008;28(11):2035–41. DOI: 10.1161/ATVBAHA.108.173930</mixed-citation></ref></ref-list></back></article>
